DEALS: Lilly buys Icos in $2.1B deal

DEALS

WHO

WITH

WHAT

SCOOP

Lilly

Icos

$2.1B buyout

The deal gives Lilly full control of ED drug tadalafil that the two companies have marketed jointly.

Stiefel Laboratories

Connetics Corporation

$640M buyout

Stiefel develops a number of prescription and non-prescription dermatological products and through the buyout, will gain Connetics' advanced therapies and topical delivery technologies.

Genzyme

AnorMed

$580M buyout

Genzyme has finally won the bidding war for AnorMed, gaining AnorMed's lead product, Mozobil, now in Phase III for hematopoietic stem cell transplantation.

Cambrex

Lonza

$460M sale

Cambrex is selling its bioproducts and biopharma business to Switzerland's Lonza Group and will use the money to pay a special dividend to shareholders.

Merck

Ambrilia Pharmaceuticals

$232M licensing deal

Canada's Ambrilia Pharmaceuticals has licensed its early-stage lead product to Merck for $17 million up front and up to $215 million in milestones.

Serono

Newron Pharmaceuticals

$200M licensing deal

Serono has won the worldwide development rights to Newron Pharmaceuticals' safinamide Parkinson's therapy.

Merck KGaA

Glenmark

$144.2M licensing deal

Merck KGaA will pay €25 million up front and up to €190 million in total to license Glenmark's DPP-4 inhibitor, GRC 8200, which is in Phase II trials.

Schering-Plough

Santarus

$70M licensing deal

The deal is for a low-dose version of the heartburn drug Zegerid.